Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Inhibitors of the Wnt/β-Catenin Signaling Pathway as Novel Anticancer Drugs
Accumulating evidence suggests that the Wnt/β-catenin signaling pathway is often involved in oncogenesis and cancer development. Accordingly, a novel anticancer drug can be developed using inhibitors of this pathway. However, at present, there is no selective inhibitor of this pathway available as a...
Main Authors: | Fumi Takahashi-Yanaga, Toshiyuki Sasaguri |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2009-01-01
|
Series: | Journal of Pharmacological Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861319312721 |
Similar Items
-
ROLE OF GSK-3 IN Wnt/β-CATENIN SIGNALING PATHWAY IN OBESITY
by: A. S. Kulakova, et al.
Published: (2021-10-01) -
Drug Development Targeting the Glycogen Synthase Kinase-3β (GSK-3β)-Mediated Signal Transduction Pathway: Role of GSK-3β in Myocardial Protection Against Ischemia/Reperfusion Injury
by: Tetsuji Miura, et al.
Published: (2009-01-01) -
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance
by: Chunyang Wang, et al.
Published: (2021-10-01) -
The Flavonol Quercitrin Hinders GSK3 Activity and Potentiates the Wnt/β-Catenin Signaling Pathway
by: Danilo Predes, et al.
Published: (2022-10-01) -
Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the Wnt/β-catenin signaling pathway
by: Yoshihara Tatsuya, et al.
Published: (2010-09-01)